Recent Developments, Recommendations for JAZZ in May

In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.